We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Fervent Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FP-101, its proprietary lead drug candidate for treating menopause symptoms, especially hot flashes.